LEADER 05391nam 2200709 450 001 9910797122703321 005 20230807215831.0 010 $a0-19-756291-4 010 $a0-19-936260-2 010 $a0-19-936259-9 035 $a(CKB)3710000000422727 035 $a(EBL)2068362 035 $a(SSID)ssj0001500034 035 $a(PQKBManifestationID)12569488 035 $a(PQKBTitleCode)TC0001500034 035 $a(PQKBWorkID)11514195 035 $a(PQKB)10793574 035 $a(MiAaPQ)EBC2068362 035 $a(StDuBDS)EDZ0002341134 035 $a(Au-PeEL)EBL2068362 035 $a(CaPaEBR)ebr11064030 035 $a(CaONFJC)MIL798067 035 $a(OCoLC)910935513 035 $a(EXLCZ)993710000000422727 100 $a20150620h20152015 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aTop drugs $ehistory, pharmacology, syntheses /$fJie Jack Li 210 1$aNew York, New York :$cOxford University Press,$d2015. 210 4$dİ2015 215 $a1 online resource (219 p.) 225 1 $aOxford scholarship online 300 $aPreviously issued in print: 2015. 311 $a0-19-936258-0 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aCover; Top Drugs History, Pharmacology, and Syntheses; Copyright; Dedication; Contents; Preface; Cardiovascular Drugs; Chapter 1: Atorvastatin Calcium (Lipitor); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS; 3.1 Discovery Route; 3.2 Process Route; 4 CONCLUDING REMARKS; 5 REFERENCES; Chapter 2: Clopidogrel Bisulfate (Plavix); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Bioavailability, Metabolism, and Toxicology; 2.2 Mechanism of Action; 2.3 Structure-Activity Relationship; 3 SYNTHESIS 327 $a3.1 Discovery Route3.2 Process Route; 3.3 Synthesis of Radio-labeled API; 4 CONCLUDING REMARKS; 5 REFERENCES; Chapter 3: Amlodipine (Novasc); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS; 3.1 Discovery Route; 3.2 Process Route; 4 CONCLUDING REMARKS; 5 REFERENCES; Cancer Drugs; Chapter 4: Paclitaxel (Taxol); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 PROCESS SEMI-SYNTHESIS; 4 TOTAL SYNTHESIS 327 $a4.1 Holton's Synthesis4.2 Nicolaou's Synthesis; 4.3 Danishefsky's Synthesis; 4.4 Wender's Synthesis; 5 CONCLUDING REMARKS; 6 REFERENCES; Chapter 5: Imatinib Mesylate (Gleevec); 1 HISTORY; 1.1 A Brief History of Cancer Drugs; 1.2 Treatments of Chronic Myeloid Leukemia; 1.3 Protein Kinase Inhibitors; 1.4 Genesis of Gleevec; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS; 3.1 Discovery Synthesis; 3.2 Process Synthesis; 4 CONCLUDING REMARKS; 5 REFERENCES; Drugs for Metabolic Diseases 327 $aChapter 6: Sitagliptin (Januvia)1 HISTORY OF DIABETES AND DIABETIC DRUGS; 1.1 Sulfonylureas; 1.2. Biguanides; 1.3 PPAR? Agonists ; 2 PHARMACOLOGY; 2.1 Mechanism of Action ; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESES; 3.1 Discovery Synthesis; 3.2 Process/Manufacturing Synthesis; 4 CONCLUDING REMARKS; 5 REFERENCES; CNS Drugs; Chapter 7: Duloxetine Hydrochloride (Cymbalta) ; 1 HISTORY OF DEPRESSION AND ANTIDEPRESSANTS; 1.1 Monoamine Oxidase Inhibitors; 1.2 Tricyclic Antidepressants; 1.3 Selective Serotonin Reuptake Inhibitors 327 $a1.4 Serotonin and Norepinephrine Reuptake Inhibitors2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology ; 3 SYNTHESIS; 3.1 Discovery Route; 3.2 Process Route; 4 CONCLUDING REMARKS; 5 REFERENCES; Chapter 8: Olanzapine (Zyprexa) ; 1 HISTORY OF SCHIZOPHRENIA AND ANTIPSYCHOTIC DRUGS ; 1.1 Typical Antipsychotics-The First Generation; 1.2 Atypical Antipsychotics-The Second Generation; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS 327 $a3.1 Discovery Route 330 8 $a'Top Drugs' provides an in-depth study on ten prominent drugs, outlining the chemistry behind each one's creation. Jie Jack Li, a medicinal chemist and an expert on drug discovery, offers a thorough analysis of the landscape of current drug development. The comprehensive text is divided by health issues, including cardiovascular, cancer, metabolic diseases, and infectious diseases. Each section features individual chapters on significant drugs, outlining the chemistry and history of the drug's discovery. 410 0$aOxford scholarship online. 606 $aDrugs$xHistory 606 $aDrugs$xDesign 606 $aPharmaceutical chemistry 615 0$aDrugs$xHistory. 615 0$aDrugs$xDesign. 615 0$aPharmaceutical chemistry. 676 $a615.1 686 $aMED071000$aSCI013060$2bisacsh 700 $aLi$b Jie Jack$0440094 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910797122703321 996 $aTop drugs$93789078 997 $aUNINA